These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23138851)

  • 1. Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity.
    Kushnareva YE; Gerencser AA; Bossy B; Ju WK; White AD; Waggoner J; Ellisman MH; Perkins G; Bossy-Wetzel E
    Cell Death Differ; 2013 Feb; 20(2):353-65. PubMed ID: 23138851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dominant optic atrophy: Culprit mitochondria in the optic nerve.
    Lenaers G; Neutzner A; Le Dantec Y; Jüschke C; Xiao T; Decembrini S; Swirski S; Kieninger S; Agca C; Kim US; Reynier P; Yu-Wai-Man P; Neidhardt J; Wissinger B
    Prog Retin Eye Res; 2021 Jul; 83():100935. PubMed ID: 33340656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling autosomal dominant optic atrophy associated with OPA1 variants in iPSC-derived retinal ganglion cells.
    Sladen PE; Jovanovic K; Guarascio R; Ottaviani D; Salsbury G; Novoselova T; Chapple JP; Yu-Wai-Man P; Cheetham ME
    Hum Mol Genet; 2022 Oct; 31(20):3478-3493. PubMed ID: 35652445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics.
    Nguyen D; Alavi MV; Kim KY; Kang T; Scott RT; Noh YH; Lindsey JD; Wissinger B; Ellisman MH; Weinreb RN; Perkins GA; Ju WK
    Cell Death Dis; 2011 Dec; 2(12):e240. PubMed ID: 22158479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.
    Zanna C; Ghelli A; Porcelli AM; Karbowski M; Youle RJ; Schimpf S; Wissinger B; Pinti M; Cossarizza A; Vidoni S; Valentino ML; Rugolo M; Carelli V
    Brain; 2008 Feb; 131(Pt 2):352-67. PubMed ID: 18222991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opa1 Deficiency Leads to Diminished Mitochondrial Bioenergetics With Compensatory Increased Mitochondrial Motility.
    Sun S; Erchova I; Sengpiel F; Votruba M
    Invest Ophthalmol Vis Sci; 2020 Jun; 61(6):42. PubMed ID: 32561926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial oxidative phosphorylation compensation may preserve vision in patients with OPA1-linked autosomal dominant optic atrophy.
    Van Bergen NJ; Crowston JG; Kearns LS; Staffieri SE; Hewitt AW; Cohn AC; Mackey DA; Trounce IA
    PLoS One; 2011; 6(6):e21347. PubMed ID: 21731710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis.
    Olichon A; Landes T; Arnauné-Pelloquin L; Emorine LJ; Mils V; Guichet A; Delettre C; Hamel C; Amati-Bonneau P; Bonneau D; Reynier P; Lenaers G; Belenguer P
    J Cell Physiol; 2007 May; 211(2):423-30. PubMed ID: 17167772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations.
    Agier V; Oliviero P; Lainé J; L'Hermitte-Stead C; Girard S; Fillaut S; Jardel C; Bouillaud F; Bulteau AL; Lombès A
    Biochim Biophys Acta; 2012 Oct; 1822(10):1570-80. PubMed ID: 22800932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Opa1 Mutation on Survival and Function of Retinal Ganglion Cells.
    González-Menéndez I; Reinhard K; Tolivia J; Wissinger B; Münch TA
    Invest Ophthalmol Vis Sci; 2015 Jul; 56(8):4835-45. PubMed ID: 26218912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atrophy.
    Yu-Wai-Man P; Davies VJ; Piechota MJ; Cree LM; Votruba M; Chinnery PF
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4561-6. PubMed ID: 19443720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.
    Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C
    Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation.
    Chun BY; Rizzo JF
    Curr Opin Ophthalmol; 2016 Nov; 27(6):475-480. PubMed ID: 27585216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy.
    Mayorov VI; Lowrey AJ; Biousse V; Newman NJ; Cline SD; Brown MD
    BMC Biochem; 2008 Sep; 9():22. PubMed ID: 18783614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OPA1: How much do we know to approach therapy?
    Del Dotto V; Fogazza M; Lenaers G; Rugolo M; Carelli V; Zanna C
    Pharmacol Res; 2018 May; 131():199-210. PubMed ID: 29454676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the
    García-López M; Jiménez-Vicente L; González-Jabardo R; Dorado H; Gómez-Manjón I; Martín MÁ; Ayuso C; Arenas J; Gallardo ME
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy.
    Williams PA; Morgan JE; Votruba M
    Brain; 2010 Oct; 133(10):2942-51. PubMed ID: 20817698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency.
    Kushnareva Y; Seong Y; Andreyev AY; Kuwana T; Kiosses WB; Votruba M; Newmeyer DD
    Cell Death Dis; 2016 Jul; 7(7):e2309. PubMed ID: 27468686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function.
    Smith TG; Seto S; Ganne P; Votruba M
    Neuroscience; 2016 Apr; 319():92-106. PubMed ID: 26820596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPA1 deficiency associated with increased autophagy in retinal ganglion cells in a murine model of dominant optic atrophy.
    White KE; Davies VJ; Hogan VE; Piechota MJ; Nichols PP; Turnbull DM; Votruba M
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2567-71. PubMed ID: 19234344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.